Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LIVN

DatePrice TargetRatingAnalyst
2/26/2025Outperform → Peer Perform
Wolfe Research
10/4/2024$65.00Buy
Goldman
9/17/2024$55.00 → $66.00Neutral → Outperform
Robert W. Baird
3/20/2024Buy
Needham
2/20/2024$60.00 → $70.00Neutral → Buy
Mizuho
9/6/2023$52.00Hold
HSBC Securities
7/19/2023$56.00Neutral
Robert W. Baird
4/14/2023$48.00Neutral
Mizuho
More analyst ratings

$LIVN
Press Releases

Fastest customizable press release news feed in the world

See more
  • LivaNova to Announce First-Quarter 2025 Results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 047836. A replay will be available on the LivaN

    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $1.02 and adjusted diluted earnings per share of $0.81 Full-year 2024 revenue of $1.25 billion increased 8.7% on a reported basis, 9.3% on a constant-currency basis, and 10.7% on an organic basis as compared to the prior-year Full-year 2024 U.S. GAAP

    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • LivaNova to Present at the Barclays Global Healthcare Conference

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event. About Liva

    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$LIVN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LIVN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LIVN
SEC Filings

See more

$LIVN
Leadership Updates

Live Leadership Updates

See more
  • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

    $ABT
    $BMY
    $IRM
    $LIVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate
  • LivaNova Appoints Susan Podlogar as a New Director

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the Board. "LivaNova's Board of Directors is pleased to welcome Susan Podlogar," said William Kozy, Chair of the Board. "Susan is a visionary leader with three decades of experience in leading business, talent, and cultural transformations at recognized global companies. She possesses a sharp understanding of the ever-changing global business landscape and will be a tremendous asset to the Board." Podlogar's career spans 30 years, holding key g

    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company's development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. "I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advanci

    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$LIVN
Financials

Live finance-specific insights

See more
  • LivaNova to Announce First-Quarter 2025 Results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 047836. A replay will be available on the LivaN

    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $1.02 and adjusted diluted earnings per share of $0.81 Full-year 2024 revenue of $1.25 billion increased 8.7% on a reported basis, 9.3% on a constant-currency basis, and 10.7% on an organic basis as compared to the prior-year Full-year 2024 U.S. GAAP

    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 982570. A re

    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$LIVN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more